ZYDUSLIFE Receives USFDA Nod for Jaythari (Deflazacort) for DMD Treatment

Published • 12 April 2025 at 5:56 AM

USFDA approves Zydus’s Jaythari tablets in multiple strengths for DMD therapy
Zydus Lifesciences receives USFDA approval for Jaythari tablets to treat Duchenne DMD
CNBCTV 18

Zydus Lifesciences Ltd (NSE: ZYDUSLIFE) has received final approval from the USFDA for its Jaythari (Deflazacort) Tablets in 6 mg, 18 mg, 30 mg, and 36 mg strengths. Jaythari is the generic version of Emflaza, used for treating Duchenne muscular dystrophy (DMD), a rare genetic disorder causing progressive muscle weakness. The drug is approved for use in patients aged 5 years and older. Jaythari will be manufactured at Doppel Farmaceutici S.r.l. in Italy, adhering to global quality standards. This approval enhances Zydus’s presence in the U.S. generics market and reflects its ongoing commitment to affordable healthcare. With Jaythari, Zydus now holds 424 USFDA approvals and has filed 492 ANDAs since FY 2003-04. Additionally, Zydus recently incorporated Zydus MedTech (France) SAS and is set to acquire 85.6% equity in Amplitude Surgical for €256.8 million. The move expands Zydus’s global footprint and medtech portfolio, aligning with its growth and innovation strategy.

Key Highlights
  • USFDA Approval: Zydus Lifesciences received final approval from the USFDA for its Jaythari (Deflazacort) Tablets.
  • Dosage Strengths: Approved in 6 mg, 18 mg, 30 mg, and 36 mg strengths.
  • Generic Launch: Jaythari is the generic version of Emflaza, used to treat Duchenne muscular dystrophy (DMD).
  • Indication: Approved for use in patients aged 5 years and older.
  • Manufacturing Location: Jaythari will be manufactured at Doppel Farmaceutici S.r.l. in Italy.
  • Market Impact: Strengthens Zydus's position in the U.S. generics market.
  • Regulatory Milestone: Zydus now holds 424 USFDA approvals and has filed 492 ANDAs since FY 2003-04.
  • Global Expansion: Incorporated Zydus MedTech (France) SAS as a wholly owned subsidiary.
  • Strategic Acquisition: Set to acquire 85.6% stake in Amplitude Surgical for €256.8 million.
  • Growth Strategy: The approval and acquisition align with Zydus’s focus on global growth and innovation in medtech.

Latest News

BPSL faces liquidation after ₹19,700 crore bid by JSW Steel deemed illegal by court

SC Orders Liquidation of Bhushan Power, Rejects JSW Steel Plan as Illegal

Published • 2 May 2025 at 7:26 AM
Reliance Power inks ₹10,000 crore deal for 930 MW solar and 1,860 MWh BESS with SECI

Reliance NU Suntech Signs ₹10,000 Crore PPA for 930 MW Solar Power

Published • 2 May 2025 at 5:44 AM
Brunson’s clutch buzzer-beater seals series and sparks iconic “double bang” from Mike Breen.

Jalen Brunson's Clutch Shot Sends Knicks to Victory; Iconic "Double Bang!"

Published • 2 May 2025 at 4:57 AM
Amazon exceeds Q1 earnings estimates but lowers Q2 guidance, citing tariffs and trade concerns.

Amazon Q1 Earnings Beat, But Soft Q2 Guidance Amid Tariff Concerns

Published • 1 May 2025 at 10:52 PM
Reddit shares soar 20% after Q1 earnings beat, revenue hits $392M with 108M daily users.

Reddit Crushes Q1 Expectations: Shares Soar 20% on Earnings

Published • 1 May 2025 at 10:37 PM
Ford April sales increase 16% with strong truck demand, but EV sales decline 40%.

Ford U.S. Sales Rise 16% in April Despite 40% EV Sales Drop

Published • 1 May 2025 at 3:26 PM
GM lowers 2025 profit forecast amid $5B tariff impact; ramps up U.S. production efforts.

GM Cuts 2025 Profit Outlook by $4B-$5B Due to US Tariffs

Published • 1 May 2025 at 3:03 PM
Barclays posts £2.7B Q1 profit, boosted by 21% rise in fixed income trading revenue.

Barclays Q1 Profit Soars 19% to £2.7B, Beats Expectations

Published • 30 April 2025 at 7:23 AM
IndusInd Bank stock gains 3% as Deputy CEO Arun Khurana resigns citing trading issues.

IndusInd Bank Deputy CEO Resigns on Loss; Stock Shows Resilience

Published • 29 April 2025 at 4:51 AM
IBM commits $150 billion for U.S. manufacturing push, focusing on quantum computing growth.

IBM to Invest $150B in US, Boost Quantum & Mainframe Production

Published • 28 April 2025 at 4:27 PM
Wells Fargo advances toward lifting $1.95 trillion asset cap after consent order termination.

Wells Fargo Clears Another Hurdle, Nears End of Consent Orders

Published • 28 April 2025 at 2:05 PM
Adani Ports to acquire North Queensland Export Terminal for $2.54B in global expansion move

Adani Ports to Acquire Australian Export Terminal for $2.54 Billion

Published • 18 April 2025 at 12:54 PM